Following a series of downgrades (three to be precise), Coloplast ended a turbulent FY15 on a better note, with Q4 15 numbers coming in slightly ahead of the more conservative market expectations (both top-line and profitability). Q4 sales were up 13% yoy to DKK3.6bn, with a 5% forex benefit complementing the robust 8% organic growth. Profitability remained strong with the adjusted EBIT increasing 14% to DKK1.2bn (margin improved by c.30bp to 34.5%). However, at the reported level, the compan ....